Ekso Bionics (NASDAQ:EKSO) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report released on Saturday. The brokerage set a “hold” rating on the stock.

Several other research analysts also recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $9.00 price target on shares of Ekso Bionics in a report on Tuesday, March 4th. Lake Street Capital dropped their price objective on Ekso Bionics from $2.00 to $1.00 and set a “buy” rating for the company in a research note on Tuesday, March 4th.

Ekso Bionics Stock Performance

Shares of EKSO opened at $0.37 on Friday. Ekso Bionics has a 52-week low of $0.34 and a 52-week high of $1.53. The stock’s 50-day simple moving average is $0.47 and its 200 day simple moving average is $0.67. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81. The stock has a market capitalization of $10.30 million, a price-to-earnings ratio of -0.56 and a beta of 1.33.

Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.07). Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. The firm had revenue of $5.09 million during the quarter, compared to analysts’ expectations of $5.05 million. Research analysts forecast that Ekso Bionics will post -0.48 EPS for the current fiscal year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.